Rocket One Inc.
RKTO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RKTO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RKTO
Rocket One Inc. (RKTO) is a pre-revenue biotech company focused on research and development, with no commercialized products and a history of operating losses funded through equity and debt securities.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Rocket One Inc..
Rocket One Inc. (RKTO) is a pre-revenue biotech company focused on research and development, with no commercialized products and a history of operating losses funded through equity and debt securities.
- As of June 30, 2026, Rocket One had cash and cash equivalents of $7.9M, working capital of $7.2M, and an accumulated deficit of $79.4M [sec_mda · as of 2026-08-14].
- Net loss for the six months ended June 30, 2026 was $6.5M, compared to $5.7M for the same period in 2025 [sec_mda · as of 2026-08-14].
- The company has never generated revenue from product sales and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-14].
- Rocket One's ability to continue as a going concern depends on raising additional capital to fund R&D activities [sec_mda · as of 2026-08-14].
What works
- The company has raised capital through equity and debt securities to fund operations, indicating some access to capital markets [sec_mda · as of 2026-08-14].
- Potential milestone payments of up to approximately $25 million could be received if all milestones in current agreements are achieved [sec_mda · as of 2026-03-27].
What to weigh
- Rocket One has incurred substantial operating losses since inception and expects to continue doing so, with no product sales to date [sec_mda · as of 2026-08-14].
- The company's cash position of $7.9M as of June 30, 2026, may be insufficient to fund operations without additional capital, raising going concern risk [sec_mda · as of 2026-08-14].
- Net cash used in operating activities increased to $6.0M for the first half of 2026 from $5.2M in the same period of 2025, reflecting rising cash burn [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $79.4M as of June 30, 2026.
“accumulated deficit of approximately $79,406,000”
SEC MD&A · August 14, 2026
Rocket One has never generated revenue from product sales.
“We have not yet commercialized any products and have never generated any revenue from product sales.”
SEC MD&A · November 12, 2025
The company's ability to continue as a going concern depends on raising additional capital.
“a going concern is dependent on our ability to raise additional capital to fund our research and development ("R&D") activities and meet our obligations on a timely basis.”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- Going concern risk — The company's ability to continue operations depends on raising additional capital; without it, operations may cease [sec_mda · as of 2026-08-14].
- No revenue from product sales — Rocket One has never generated product revenue and expects continued losses, with no commercialized products [sec_mda · as of 2026-08-14].
- Increasing cash burn — Net cash used in operating activities rose to $6.0M in H1 2026 from $5.2M in H1 2025, indicating accelerating cash consumption [sec_mda · as of 2026-08-14].
What to watch
- Ability to raise additional capital through equity or debt offerings to fund ongoing R&D and operations [sec_mda · as of 2026-08-14].
- Progress in pre-clinical and clinical development of product candidates, as no products are yet commercialized [sec_mda · as of 2026-08-14].
- Achievement of development or commercialization milestones that could trigger milestone payments of up to $25M [sec_mda · as of 2026-03-27].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Rocket One Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rocket One Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.2 months
D/E 0.17 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$605K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 259,382 | $218K |
| geode capital management, llc | 214,244 | $180K |
| vanguard fiduciary trust co | 84,318 | $71K |
| state street corp | 63,939 | $54K |
| northern trust corp | 42,054 | $35K |
| xtx topco ltd | 18,129 | $15K |
| two sigma securities, llc | 14,896 | $13K |
| morgan stanley | 10,006 | $8K |
| tower research capital llc (trc) | 7,355 | $6K |
| osaic holdings, inc. | 2,701 | $2K |
Showing top 10 of 16 institutional holders of Rocket One Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 4.8%
- Days to cover
- 1.9
- Shares short
- 749,807
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RKTO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rocket One Inc.?
Rocket One Inc. (RKTO) is a pre-revenue biotech company focused on research and development, with no commercialized products and a history of operating losses funded through equity and debt securities.
Who is the CEO of Rocket One Inc.?
Mr. Robb Knie is the chief executive officer of Rocket One Inc. (RKTO).
Where is Rocket One Inc. headquartered?
Rocket One Inc. (RKTO) is headquartered in Hoboken, NJ, United States.
What therapeutic areas does Rocket One Inc. focus on?
Rocket One Inc. develops therapies across Oncology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.